LATEST
Tue, Nov 17, 2026
Loading weather...
Markets

SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive...

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data. The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia...

SOURCE: Benzinga
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

Soybeans Holding Near Unchanged Early on Tuesday

Soybeans are trading with fractionally mixed action early on Tuesday. Futures po...

Read Article »

Dow Movers: UNH, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list o...

Read Article »

Cattle Look to Tuesday Following Weaker Start to the Week

Live cattle futures were down 32 cents to $1.15 at the final bell. Cash trade la...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.